Comparative Pharmacology
Head-to-head clinical analysis: DRIXORAL versus MOTPOLY XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIXORAL versus MOTPOLY XR.
DRIXORAL vs MOTPOLY XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drixoral is a combination product containing dexbrompheniramine maleate, a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, and pseudoephedrine sulfate, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
MOTPOLY XR is a combination of an opioid agonist (morphine) and an opioid antagonist (naltrexone). The extended-release formulation allows for sequential release: an initial morphine dose followed by naltrexone, which mitigates opioid-induced adverse effects by antagonizing mu-opioid receptors in the gastrointestinal tract without affecting central analgesia.
One pseudoephedrine 60 mg and dexbrompheniramine 2 mg tablet orally every 12 hours; maximum 2 tablets per 24 hours.
Adults: 10 mg orally once daily, with or without food.
None Documented
None Documented
Dexbrompheniramine: 12-15h (prolonged in renal impairment). Pseudoephedrine: 5-8h (alkaline urine slows elimination, half-life up to 20h).
Terminal half-life 12–15 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Drixoral contains dexbrompheniramine (renal: 30-50% unchanged, rest metabolites) and pseudoephedrine (renal: 70-90% unchanged, pH-dependent).
Renal: ~60% unchanged; biliary/fecal: ~25% as metabolites; <5% unchanged in feces.
Category C
Category C
Antihistamine/Decongestant
Decongestant/Antihistamine Combination